Actually, combining a PI3K inhibitor with a small molecule inhibitor of EGFR/HER2/HER3 signaling was shown to have synergistic growth inhibition in breast cancer cell lines in vitro, suggesting that this is a strategy that might be a possible treatment option to be tested in future clinical trials [91]. Here, ERBB3 is linked to breast cancer.